Strategic partnerships BioAscent has a track record of collaborating with academic institutions and industry partners (University of Edinburgh, Keltic Pharma) to advance targeted discovery programs, presenting opportunities for co-development projects and access to their peptide discovery and GPCR platforms.

GPCR focus Recent partnerships emphasize GPCR-targeted peptide discovery, suggesting a potential fit for biotechnology, pharma, and biotech clients seeking novel GPCR modulation or peptide therapeutics, as well as access to their internal peptide libraries and screening capabilities.

Expanded facilities The company expanded its Newhouse facilities and launched advanced protein production capabilities, enabling scale-up for preclinical protein production, protein engineering services, and larger screening campaigns for partners.

Integrated discovery With de novo assay development, HTS, medicinal chemistry, computational chemistry, and compound management under one roof and 1.5 million compounds managed, BioAscent offers end-to-end drug discovery services that can shorten timelines and simplify vendor management for customers.

Regional advantage Located in Scotland with recent US expansion leadership, BioAscent can position itself as a gateway for North American sponsors seeking European access, potential offshoring of early programs, and proximity to UK research ecosystems.